Life-extending pancreatic cancer medicine recommended by NICE in final guidance
The pivotal Phase III study demonstrated that treatment with Abraxane in combination with gemcitabine can offer patients a median overall survival improvement of 1.8 months.
The National Institute for Health and Care Excellence (NICE) has issued final technology appraisal guidance recommending the use of nab-Paclitaxel in combination with gemcitabine, in eligible patients, for the first-line treatment of a type of metastatic pancreatic cancer, known as metastatic pancreatic ductal adenocarcinoma (mPDAC). This decision means that no appeals have been received against the Final Appraisal Determination (FAD) and nab-Paclitaxel in combination with gemcitabine is now an option for mPDAC adult patients in England via the NHS when other combination chemotherapies are unsuitable and they would otherwise have gemcitabine monotherapy.
Dr Stephen Falk, Consultant Clinical Oncologist, University Hospitals Bristol NHS Trust and Chair of the NCRI Pancreatic Cancer Subgroup commented: “Metastatic pancreatic cancer has an average life expectancy of 2-6 months post diagnosis, and this has shown minimal improvement in the last 40 years. The clinical community welcomes this recommendation of nab-Paclitaxel in combination with gemcitabine for the treatment of metastatic pancreatic cancer from NICE, which provides an alternative treatment option for appropriate patients in this area of unmet need. I also welcome the potential of extra survival this regimen may offer to the right patient compared to gemcitabine alone.
Ali Stunt, Founder and CEO of Pancreatic Cancer Action, added: “Today’s decision is welcome news for patients with metastatic pancreatic cancer and their families. After many months of campaigning to bring access in line with other nations in the UK, the final guidance issued today will bring equality of access across Great Britain to the patient community. We are pleased that NICE has recognised the importance of new treatment options in this area of unmet medical need.”
Results from the Phase III MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial) demonstrated an increase in median overall survival of 1.8 months with nab-Paclitaxel in combination with gemcitabine, when compared to gemcitabine alone in first-line treatment of mPDAC [median overall survival (8.5 months vs. 6.7 months, respectively). A post-hoc updated overall survival analysis with an additional 8-month data cut-off confirms the results seen in the Phase III MPACT trial.
Remo Gujer, General Manager at Celgene UK & Ireland commented: “We are delighted that, after reviewing the evidence in our resubmission, NICE has recognised the importance of this treatment combination for metastatic pancreatic cancer patients. We are pleased that appropriate patients in Great Britain will now have access to treatment options such as nab-Paclitaxel and we will continue our research in this area of considerable unmet need.”
The treatment of pancreatic cancer remains an area of unmet need, with around 8 in 10 cases diagnosed at a late stage in England and Scotland. Survival rates have shown minimal improvement over the past 40 years and the disease has one of the worst 5-year survival rates of common cancers in England and Wales. In the 1970s, 1% of people diagnosed with pancreatic cancer survived their disease beyond 10 years; today it is still approximately 1%. Every day in the UK there are approximately 26 new diagnoses of pancreatic cancer, as well as an estimated 24 deaths due to this disease.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance